Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion center.

GSK5764227 has been granted FDA breakthrough therapy designation, potentially expediting its development as a treatment for relapsed/refractory osteosarcoma.

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.

Frontline treatment with belzutifan and cabozantinib resulted in durable responses and a manageable safety profile in patients with previously untreated advanced ccRCC.

Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.

Sasanlimab plus BCG improved outcomes in high-risk, BCG-naive non-muscle-invasive bladder cancer.

An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.

The FDA has released draft guidance with recommendations on tissue biopsies in clinical trials for adults and children.

Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.

Sunvozertinib received FDA priority review for advanced EGFR exon 20 insertion-positive non-small cell lung cancer progressing after chemotherapy.

In patients with RRMM, subcutaneous isatuximab plus Pd resulted in a non-inferior objective response rate (ORR) and comparable pre-dose concentrations at steady state compared to IV isatuximab plus Pd.

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have progressed after PD-(L)1 therapy.

Ropeginterferon alfa-2b showed superior efficacy over anagrelide in the SURPASS-ET trial for essential thrombocythemia, with higher durable response rates and greater JAK2 allele burden reduction.

Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that patients and caregivers fully understand their choices and make informed decisions.

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.

Amivantamab and lazertinib improved overall survival compared to osimertinib as a first-line treatment for advanced or metastatic EGFR-mutant NSCLC.

While the phase 2 trial did not meet its primary endpoint, it demonstrated that SBRT plus concurrent radiotherapy yielded better results than those observed in previous studies.

Updated results from the phase 3 CheckMate-8HW trial continue to show fewer severe (grade 3/4) side effects with nivolumab/ipilimumab compared to chemotherapy.

Panelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.

Analysis of two trials indicates psilocybin-assisted psychotherapy may benefit the mental health of patients with cancer.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with infrequent surgical complications.

A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.

A combination of avutometinib and defactinib has been granted priority review by the FDA for the treatment of KRAS-mutant recurrent low-grade serous ovarian cancer.